Company Presentation


Category:Emerging Biotech Company
Date:April 22, 2024
Time:15:15 – 15:30
Speaker:Dr. Peter Schiemann, CEO & Chairman

Company profile

Ymmunobio was founded in 2021 focusing on GI cancers with our lead indication of gastric cancer. Our new and first in class Antibody Drug Conjugate (ADC) candidate (YB-800) has a vast potential in addressing GI cancer. The new receptor target is present on 50% of GI cancers. Ymmunobio functions as a completely virtual company. Our team consists of very experienced Subject Matter Experts who have been working in the industry for decades.

Further information